Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

Novo Nordisk Pakistan hosted “Unordinary Partnerships to Shape a Healthier Tomorrow” that brought together healthcare ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...